Cargando…

How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma

SIMPLE SUMMARY: HCC is a very aggressive disease and patients diagnosed in an advanced/metastatic setting obtain poor survival outcomes with standard treatments. In recent years, the introduction of immunotherapy strategies, such as immune checkpoint inhibitors as single agents and in combination wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martini, Giulia, Ciardiello, Davide, Paragliola, Fernando, Nacca, Valeria, Santaniello, Walter, Urraro, Fabrizio, Stanzione, Maria, Niosi, Marco, Dallio, Marcello, Federico, Alessandro, Selvaggi, Francesco, Della Corte, Carminia Maria, Napolitano, Stefania, Ciardiello, Fortunato, Martinelli, Erika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466991/ https://www.ncbi.nlm.nih.gov/pubmed/34572944 http://dx.doi.org/10.3390/cancers13184719

Ejemplares similares

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
por: Troiani, Teresa, et al.
Publicado: (2016)

Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data
por: Sardo, Emilia, et al.
Publicado: (2022)

Beyond N staging in colorectal cancer: Current approaches and future perspectives
por: Arrichiello, Gianluca, et al.
Publicado: (2022)

Implication of the Hedgehog pathway in hepatocellular carcinoma
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
por: Caputo, Vincenza, et al.
Publicado: (2023)

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
por: Martini, Giulia, et al.
Publicado: (2017)

Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota
por: Morgillo, Floriana, et al.
Publicado: (2018)

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

Mechanisms of resistance to EGFR-targeted drugs: lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2016)

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives
por: Ciaramella, Vincenza, et al.
Publicado: (2018)

Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
por: Arrichiello, Gianluca, et al.
Publicado: (2022)

Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy
por: Fasano, Morena, et al.
Publicado: (2015)

Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2014)

Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic
por: Napolitano, Stefania, et al.
Publicado: (2022)

Role and targeting of anaplastic lymphoma kinase in cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
por: Fasano, Morena, et al.
Publicado: (2022)

Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series
por: Guerrera, Luigi Pio, et al.
Publicado: (2022)

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
por: Papaccio, Federica, et al.
Publicado: (2018)

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
por: Vitiello, Pietro Paolo, et al.
Publicado: (2021)

Towards the era of precision medicine in metastatic colorectal cancer
por: Napolitano, Stefania, et al.
Publicado: (2020)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Corte, Carminia Maria Della, et al.
Publicado: (2022)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
por: Caputo, Vincenza, et al.
Publicado: (2022)

Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype
por: Ciardiello, Davide, et al.
Publicado: (2021)

Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy
por: Fasano, Morena, et al.
Publicado: (2021)

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF(V600E)-Mutant Colorectal Cancer
por: Napolitano, Stefania, et al.
Publicado: (2023)

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
por: Napolitano, Stefania, et al.
Publicado: (2017)

Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis
por: D’Abrosca, Brigida, et al.
Publicado: (2019)

Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors
por: Fasano, Morena, et al.
Publicado: (2021)

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
por: Martini, Giulia, et al.
Publicado: (2023)

Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Napolitano, Stefania, et al.
Publicado: (2023)

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells
por: Ciaramella, Vincenza, et al.
Publicado: (2018)

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells
por: Della Corte, Carminia Maria, et al.
Publicado: (2015)

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
por: Della Corte, Carminia Maria, et al.
Publicado: (2019)

Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC
por: Ciaramella, Vincenza, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rjml247dh8vkj82esk5sngto1h